Healthcare, as tracked by the XLV ETF, is outperforming Consumer Staples’ XLP on a range of defensive measures that matter to investors weighing protection against downside risk. Across volatility, risk-adjusted returns, and recent performance, XLV posts the stronger profile — even as XLP retains advantages that appeal to income-seeking portfolios.
The Scorecard
| Metric | XLV (Healthcare) | XLP (Consumer Staples) | Edge |
|---|---|---|---|
| Beta (5Y) | 0.26 | 0.45 | XLV |
| 1Y Return | +23.95% | +6.15% | XLV |
| YTD Return | +6.05% | +9.92% | XLP |
| 3M Return | +13.04% | +1.62% | XLV |
| Dividend Yield | 1.56% | 2.59% | XLP |
| Sharpe Ratio | 1.39 | 0.41 | XLV |
| Alpha | +16.68 | -1.31 | XLV |
| P/E (LTM) | 19.49x | 20.34x | XLV |
| ROIC | 16.8% | 14.5% | XLV |
| AUM | $41.7B | $14.6B | XLV |
Why Healthcare Is Leading
The most striking metric is the beta gap. XLV’s five-year beta of 0.26 indicates substantially lower volatility versus XLP’s 0.45, which is itself considered low. On a risk-adjusted basis, XLV’s Sharpe ratio of 1.39 far exceeds XLP’s 0.41, signaling that Healthcare has delivered better returns per unit of risk. The alpha figures underline this pattern: Healthcare shows a positive alpha of +16.68, while Consumer Staples posts an alpha of -1.31, implying XLV has added active excess return while XLP has roughly tracked broader benchmarks.
Concentration and Contribution
Healthcare’s gains are concentrated in a handful of large components. Eli Lilly (LLY) represents 15.5% of XLV and is noted as rising +4.29% on the day referenced. AbbVie (ABBV) and Amgen (AMGN) are also named contributors, with ABBV up +2.14% and AMGN up +6.35% on the same day. The sector blends non-cyclical demand for medications with pockets of innovation-driven growth, a combination that can support both defensive characteristics and above-average returns.
The Case for Consumer Staples
Consumer Staples still presents a compelling profile for certain investors. XLP’s dividend yield of 2.59% exceeds XLV’s 1.56%, making it a more attractive choice for income-focused strategies, including retirees. The risk score cited in the source material indicates marginally lower total risk for XLP (1.46 vs. 1.97). Holdings such as Coca-Cola (KO), Philip Morris (PM), and Costco (COST) are highlighted as cash-flow-oriented businesses with pricing power. Notably, XLP’s year-to-date return of +9.92% exceeds XLV’s +6.05% in 2026 specifically, suggesting Staples has been favored during part of the current-year defensive rotation.
Practical Takeaways
- For investors prioritizing total return combined with defensive characteristics, XLV shows a superior risk-adjusted profile.
- For those prioritizing income and lower headline volatility, XLP’s higher yield and steady cash-flow names remain appealing.
- An allocation that includes both sectors could provide complementary defensive exposures.
Bottom Line
On the basis of the metrics presented, Healthcare wins the battle for defense when measured by volatility, Sharpe ratio, alpha, and recent trailing returns. Consumer Staples retains a clear role as the higher-yield, lower-drama option for income-oriented investors. The data suggest a case for holding both ETFs within a defensive sleeve, depending on investor objectives.